Exelixis Cabometyx Neuroendocrine Trial Falls Short of High Investor Bar
1h ago|4 min readStandard
Fazen Markets Editorial Desk
Collective editorial team · methodology
exelixiscabometyx
Fazen Markets Editorial Desk
Collective editorial team · methodology
Trades XAUUSD 24/5 on autopilot. Verified Myfxbook performance. Free forever.
Risk warning: CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. The majority of retail investor accounts lose money when trading CFDs. Vortex HFT is informational software — not investment advice. Past performance does not guarantee future results.
Exelixis, Inc. (Nasdaq: EXEL) announced topline results from its CABINET pivotal trial on 30 May 2026. The phase 3 study evaluated Cabometyx (cabozantinib) in patients with advanced pancreatic and extra-pancreatic neuroendocrine tumors. While the trial demonstrated a positive trend in progression-free survival, it did not meet its primary endpoint of statistical significance in the overall population. The company's stock declined sharply by 8% in after-hours trading following the data release, reflecting investor disappointment against high expectations for label expansion.
The announcement is a significant event for Exelixis, which derives over 90% of its revenue from Cabometyx. The drug is currently approved for advanced renal cell carcinoma, hepatocellular carcinoma, and differentiated thyroid cancer. Neuroendocrine tumors (NETs) represented one of the company's most important late-stage pipeline opportunities to diversify its revenue base and drive future growth beyond its core oncology indications.
The last major label expansion for Cabometyx came in September 2021, when the FDA approved it for previously treated radioactive iodine-refractory differentiated thyroid cancer. That approval was based on the COSMIC-311 trial, where cabozantinib demonstrated a 78% reduction in the risk of disease progression or death versus placebo. Success in the CABINET trial would have opened access to a NET market with high unmet need where current standard-of-care treatments, including somatostatin analogs and targeted therapies like everolimus, offer limited efficacy.
The immediate catalyst for the current event was the pre-specified interim analysis of the CABINET trial. Investor optimism had been building due to a strong scientific rationale; cabozantinib's mechanism of inhibiting multiple tyrosine kinases, including MET, AXL, and VEGFR, targets pathways implicated in NET growth and angiogenesis. The high bar for success was set against the competitive landscape, where recent data from other agents had raised expectations.
The primary endpoint of the CABINET trial was progression-free survival (PFS) in the overall population of patients with advanced pancreatic and extra-pancreatic NETs. The trial did not achieve statistical significance for this primary endpoint at the interim analysis. Preliminary data indicated a median PFS for the cabozantinib arm that was numerically longer than the placebo arm, but the difference did not cross the pre-defined statistical threshold.
Exelixis reported that a pre-specified subgroup analysis showed a more pronounced treatment effect in patients with pancreatic NETs. The hazard ratio for this subgroup favored cabozantinib, suggesting a differential response based on tumor origin. The safety profile of cabozantinib in the trial was consistent with its known adverse event spectrum, including diarrhea, fatigue, and hypertension.
The market reaction was immediate and severe. EXEL shares traded down 8% to approximately $22.50 in extended trading following the announcement, erasing nearly $1.5 billion in market capitalization. This contrasts with the 12% year-to-date gain the stock had posted before the news, which had outpaced the iShares Biotechnology ETF (IBB), up only 5% for the year. The 8% drop is comparable to the 9% decline Exelixis experienced in November 2018 when the CELESTIAL trial for cabozantinib in previously treated hepatocellular carcinoma showed a survival benefit but raised questions about tolerability.
The missed primary endpoint limits Cabometyx's immediate commercial runway. Analysts had modeled peak NET sales potential between $300 million and $500 million. This revenue is now at risk or delayed, increasing pressure on the company's other pipeline assets, including zanzalintinib in colorectal cancer. The news is a relative positive for established NET players like Novartis AG (NVS), maker of everolimus, and Ipsen, which markets the somatostatin analog lanreotide. Both companies may face less competitive pressure in the near term.
A key limitation of the analysis is that full trial data, including overall survival and quality-of-life metrics, are not yet available. The subgroup signal in pancreatic NETs could still support a regulatory filing for a more limited indication, though the commercial opportunity would be smaller. The outcome also highlights the difficulty of achieving statistical significance in heterogeneous cancer populations like NETs, where patient biology varies widely.
Positioning data indicates institutional holders were net long EXEL heading into the event, with a short interest ratio of just 3.5 days to cover. The sharp sell-off likely triggered stop-loss orders and forced liquidations from momentum funds. Flow is expected to rotate towards companies with clearer late-stage catalysts in oncology, such as Mirati Therapeutics (MRTX) with its KRAS inhibitors, and towards large-cap biopharma names seen as more defensive.
Investor focus will shift to Exelixis's second-quarter earnings call, scheduled for late July 2026. Management will provide a detailed breakdown of the CABINET data and outline the regulatory path forward, if any, for cabozantinib in NETs. The company may also provide updates on its other pivotal trials, including STELLAR-303 for zanzalintinib in non-small cell lung cancer, with data expected in early 2027.
Key technical levels for EXEL stock include the 200-day simple moving average near $21.80, which acted as support in April 2026. A breach below that level could see a test of the 52-week low of $19.45. Resistance now stands at the pre-announcement level of $24.50, which aligns with the 50-day moving average.
Market participants will also monitor the ASCO 2026 Gastrointestinal Cancers Symposium in January 2027, where full data from the CABINET trial is likely to be presented. The presentation's reception by clinical oncologists will be critical for assessing any remaining commercial potential. Concurrently, data readouts from competitors, such as new combinations in NETs, will reshape the competitive landscape Exelixis faces.
Neuroendocrine tumors (NETs) are a rare and heterogeneous group of cancers that arise from neuroendocrine cells throughout the body, most commonly in the gastrointestinal tract and lungs. They are challenging to treat because they are often diagnosed at an advanced stage, grow slowly making response assessment difficult, and can secrete hormones causing debilitating symptoms. Current therapies, including somatostatin analogs, targeted mTOR inhibitors, and peptide receptor radionuclide therapy, often provide disease stabilization but limited tumor shrinkage, creating a high unmet need for more effective agents.
Vortex HFT is our free MT4/MT5 Expert Advisor. Verified Myfxbook performance. No subscription. No fees. Trades 24/5.
Position yourself for the macro moves discussed above
Start TradingSponsored
Open a demo account in 30 seconds. No deposit required.
CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.